Top

Published in:

Open Access 01-12-2012 | Review

Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer

Authors: Rolf F Barth, MGraca H Vicente, Otto K Harling, WS Kiger III, Kent J Riley, Peter J Binns, Franz M Wagner, Minoru Suzuki, Teruhito Aihara, Itsuro Kato, Shinji Kawabata

Published in: Radiation Oncology | Issue 1/2012

Abstract

Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high grade gliomas, recurrent cancers of the head and neck region and either primary or metastatic melanoma. Neutron sources for BNCT currently have been limited to specially modified nuclear reactors, which are or until the recent Japanese natural disaster, were available in Japan, the United States, Finland and several other European countries, Argentina and Taiwan. Accelerators producing epithermal neutron beams also could be used for BNCT and these are being developed in several countries. It is anticipated that the first Japanese accelerator will be available for therapeutic use in 2013. The major hurdle for the design and synthesis of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations in the range of 20 μg/g. This would be sufficient to deliver therapeutic doses of radiation with minimal normal tissue toxicity. Two boron drugs have been used clinically, a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine or “BPA”, and sodium borocaptate or “BSH” (Na₂B₁₂H₁₁SH). In this report we will provide an overview of other boron delivery agents that currently are under evaluation, neutron sources in use or under development for BNCT, clinical dosimetry, treatment planning, and finally a summary of previous and on-going clinical studies for high grade gliomas and recurrent tumors of the head and neck region. Promising results have been obtained with both groups of patients but these outcomes must be more rigorously evaluated in larger, possibly randomized clinical trials. Finally, we will summarize the critical issues that must be addressed if BNCT is to become a more widely established clinical modality for the treatment of those malignancies for which there currently are no good treatment options.

Available only for authorised users

Barth RF, Coderre JA, Vicente MG, Blue TE: Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005, 11: 3987-4002. 10.1158/1078-0432.CCR-05-0035PubMed

Slatkin DN: A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit. Brain 1991, 114: 1609-1629. 10.1093/brain/114.4.1609PubMed

Barth RF: Boron neutron capture therapy: a critical assessment. J Neurooncol 2003, 62: 1-210.PubMed

Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, Ono K, Harada T: First clinical case of boron neutron capture therapy for head and neck malignancies using 18 F-BPA PET. Head Neck 2006, 28: 850-855. 10.1002/hed.20418PubMed

Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M, Yura Y: Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 2004, 61: 1069-1073. 10.1016/j.apradiso.2004.05.059PubMed

Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, Imahori Y, Suzuki M, Sakrai Y, Sumi T, et al.: Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot 2009, 67: S37-S42. 10.1016/j.apradiso.2009.03.103PubMed

Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Valimaki P, et al.: Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys 2012, 82: e67-e75. 10.1016/j.ijrobp.2010.09.057PubMed

Altieri S, Barth RF, Bortolussi S, Roveda L, Zonta A: In 13th International Congress on Neutron Capture Therapy, A New Option Against Cancer. Appl Radiat Isot 2009, 67: S1-S379. 10.1016/j.apradiso.2009.03.009PubMed

Kreiner A: 14th International Congress on Neutron Capture Therapy. Appl Radiat Isot 2011, 69: 1631-1939.

10.

Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG: The chemistry of neutron capture therapy. Chem Rev 1998, 98: 1515-1562. 10.1021/cr941195uPubMed

11.

Sibrian-Vazquez M, Vicente MGH: Boron tumor-delivery for BNCT: Recent developments and perspectives. In Boron Science: New Technologies & Applications. Edited by: Hosmane NS. CRC Press; 2011:203-232.

12.

Semioshkin A, Nizhnik E, Godovikov I, et al.: Reactions of oxonium derivatives of [B12H12]2− with amines: Synthesis and structure of novel B12-based ammonium salts and amino acids. V J Organomet Chem 2007, 692: 4020-4028. 10.1016/j.jorganchem.2007.06.001

13.

Kabalka GW, Wu Z, Yao M-L: Synthesis of a series of boronated unnatural cyclic amino acids as potential boron capture therapy agents. Appl Organomet Chem 2008, 22: 516-522. 10.1002/aoc.1435

14.

Kabalka GW, Yao ML, Marepally SR, Chandra S: Biological evaluation of boronated unnatural amino acids as new boron carriers. Appl Radiat Isot 2009, 67: S374-S379. 10.1016/j.apradiso.2009.03.104PubMedCentralPubMed

15.

Mier W, Gabel D, Haberkorn U: Conjugation of the closo-borane mereaptoundeca-hydrododecaborate (BSH) to a tumor selective peptide. Anorg Allg Chem 2004, 630: 1258-1262. 10.1002/zaac.200400064

16.

Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, Eriksson S: Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res 2004, 64: 6280-6286. 10.1158/0008-5472.CAN-04-0197PubMed

17.

Barth RF, Yang W, Wu G, Swindall M, Byun Y, Narayanasamy S, Tjarks W, Tordoff K, Moeschberger ML, Eriksson S, et al.: Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. Proc Natl Acad Sci U S A 2008, 105: 17493-17497. 10.1073/pnas.0809569105PubMedCentralPubMed

18.

Bregadze VI, Sivaev IB, Lobanova IA, Titeev RA, Brittal DI, Grin MA, Mironov AF: Conjugates of boron clusters with derivatives of natural chlorin and bacteriochlorin. Appl Radiat Isot 2009, 67: S101-S104. 10.1016/j.apradiso.2009.03.024PubMed

19.

Renner MW, Miura M, Easson MW, Vicente MG: Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy. Anticancer Agents Med Chem 2006, 6: 145-157. 10.2174/187152006776119135PubMed

20.

Ol'shevskaya V, Zaytsev A, Savchenko A, et al.: Boronated porphyrins and chlorins as potential anticancer drugs. Bull Korean Chem Soc 2007, 28: 1910-1916.

21.

Kahl S, Koo M: Synthesis and properties of tebrakis-carborane-carboxylate esters of 2;4-bis (−dehydroryethyl) dereteroporphyrin IX. In Progress Neutron Capture Therapy. Edited by: Allen B, Moore D, Harrington B. Plenium Press, New York; 1992:223-226.

22.

Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ: Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem 2007, 18: 101-108. 10.1021/bc060174rPubMedCentralPubMed

23.

Nakamura H: Liposomal boron delivery system for neutron capture therapy of cancer. In Boron Science: New Technologies and Applications. Edited by: Hosmane N. CRC Press; 2012:165-179.

24.

Altieri S, Balzi M, Bortolussi S, Bruschi P, Ciani L, Clerici AM, Faraoni P, Ferrari C, Gadan MA, Panza L, et al.: Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. J Med Chem 2009, 52: 7829-7835. 10.1021/jm900763bPubMed

25.

Feakes DA: Design and development of polyhedral borane anions for liposomal delivery. In Boron Science: New Technologies and Applications. Volume 12. Edited by: Hosmane NS. CRC Press; 2011:277-292.

26.

Li T, Hamdi J, Hawthorne MF: Unilamellar liposomes with enhanced boron content. Bioconjug Chem 2006, 17: 15-20. 10.1021/bc0501350PubMed

27.

Capala J, Barth RF, Bendayan M, Lauzon M, Adams DM, Soloway AH, Fenstermaker RA, Carlsson J: Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug Chem 1996, 7: 7-15. 10.1021/bc950077qPubMed

28.

Wu G, Yang W, Barth RF, Kawabata S, Swindall M, Bandyopadhyaya AK, Tjarks W, Khorsandi B, Blue TE, Ferketich AK, et al.: Molecular targeting and treatment of an epidermal growth factor receptor positive glioma using boronated cetuximab. Clin Cancer Res 2007, 13: 1260-1268. 10.1158/1078-0432.CCR-06-2399PubMed

29.

Yang W, Wu G, Barth RF, Swindall MR, Bandyopadhyaya AK, Tjarks W, Tordoff K, Moeschberger M, Sferra TJ, Binns PJ, et al.: Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res 2008, 14: 883-891. 10.1158/1078-0432.CCR-07-1968PubMed

30.

Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BT, Tjarks W, Barth RF, Claffey K, Backer JM: Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 2005, 4: 1423-1429. 10.1158/1535-7163.MCT-05-0161PubMed

31.

Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, et al.: Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 2006, 12: 3792-3802. 10.1158/1078-0432.CCR-06-0141PubMed

32.

Yang W, Barth RF, Wu G, Huo T, Tjarks W, Ciesielski M, Fenstermaker RA, Ross BD, Wikstrand CJ, Riley KJ, Binns PJ: Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors. J Neurooncol 2009, 95: 355-365. 10.1007/s11060-009-9945-xPubMedCentralPubMed

33.

Yang W, Barth RF, Wu G, Tjarks W, Binns P, Riley K: Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot 2009, 67: S328-S331. 10.1016/j.apradiso.2009.03.030PubMed

34.

Crossley EL, Ziolkowski EJ, Coderre JA, Rendina LM: Boronated DNA-binding compounds as potential agents for boron neutron capture therapy. Mini Rev Med Chem 2007, 7: 303-313. 10.2174/138955707780059808PubMed

35.

Zhu Y, Yan K, Maguire J, et al.: Recent developments in boron neutron capture therapy (BNCT) driven by nanotechnology. Curr Chem Biol 2007, 1: 141-149. 10.2174/187231307780636431

36.

Yinghuai Z, Cheng Yan K, Maguire JA: Recent developments in boron neutron capture therapy driven by nanotechnology. In Boron Science: New Technologies and Applications. Volume 1. Edited by: Hosmane NS. CRC Press; 2007:147-163.

37.

Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, et al.: Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 2008, 87: 287-294. 10.1007/s11060-008-9522-8PubMed

38.

Ito Y, Kimura Y, Shimahara T, Ariyoshi Y, Shimahara M, Miyatake S, Kawabata S, Kasaoka S, Ono K: Disposition of TF-PEG-Liposome-BSH in tumor-bearing mice. Appl Radiat Isot 2009, 67: S109-S110. 10.1016/j.apradiso.2009.03.018PubMed

39.

Pietrangeli D, Ricciardi G: Neutral and polyanionic carboranylporphyrazines: synthesis and physico-chemical properties. Appl Radiat Isot 2009, 67: S97-S100. 10.1016/j.apradiso.2009.03.023PubMed

40.

Menichetti L, De Marchi D, Calucci L, Ciofani G, Menciassi A, Forte C: Boron nitride nanotubes for boron neutron capture therapy as contrast agents in magnetic resonance imaging at 3 T. Appl Radiat Isot 2011, 69: 1725-1727. 10.1016/j.apradiso.2011.02.032PubMed

41.

42.

Orlova A, Kononov LO, Kimel BG, et al.: Conjugates of polyhedral boron compounds with carbohydrates. 4. Hydrolytic stability of carborane-lactose conjugates depends on the structure of a spacer between the carborane cage and sugar moiety. Appl Organometal Chem 2006, 20: 416-420. 10.1002/aoc.1082

43.

Moss RL, Aizawa O, Beynon D, Brugger R, Constantine G, Harling O, Liu HB, Watkins P: The requirements and development of neutron beams for neutron capture therapy of brain cancer. J Neurooncol 1997, 33: 27-40. 10.1023/A:1005704911264PubMed

44.

Harling OK: Fission reactor based epithermal neutron irradiation facilities for routine clinical application in BNCT–Hatanaka memorial lecture. Appl Radiat Isot 2009, 67: S7-S11. 10.1016/j.apradiso.2009.03.095PubMed

45.

Harling OK, Riley KJ: Fission reactor neutron sources for neutron capture therapy - a critical review. J Neurooncol 2003, 62: 7-17.PubMed

46.

Zhou Y, Gao Z, Li Y, Guo C, Liu X: Design and construction of the in-hospital neutron irradiator-1(HNI). In Proceed of 12th ICNCT - Advances in Neutron Capture Therapy 2006; October 9–13; Takamatsu, Japan. Edited by: Nakagawa Y, Kobayashi T, Fukuda H. 2006, 557-560.

47.

Li Y, Xia P, Wang X, Kong F, Huang Q: Start-up of the first in-hospital Neutron Irradiator (IHNI1) & presentation of the BNCT development status in China. In Proc 14th Int’l Cong on Neutron Capture Therapy, New Challenges in Neutron Capture Therapy 2010 Oct 25–29; Buenos Aires, Argentina. Edited by: Liberman S, Kreiner AJ, Casal MR, Menendez P, Schwint A, Dragosa A, Cruz GS. 2010, 371-374.

48.

Harling OK, Riley KJ, Newton TH, et al.: The fission converter based epithermal neutron ir-radiation facility at the Massachusetts Institute of Technology Reactor. Nucl Sci Eng 2002, 140: 223-240.

49.

Riley KJ, Binns PJ, Harling OK: Performance characteristics of the MIT fission converter based epithermal neutron beam. Phys Med Biol 2003, 48: 943-958. 10.1088/0031-9155/48/7/310PubMed

50.

Blue TE, Yanch JC: Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors. J Neurooncol 2003, 62: 19-31.PubMed

51.

Nigg DW: Neutron sources and applications in radiotherapy- A brief history and current trends. In Advances in Neutron Capture Therapy 2006 - Proc 12th Intl Cong Neutron Capture Therapy; Oct 9–13. Edited by: Nakagawa Y, Kobayashi T, Fukuda H. Takamatsu, Japan; 2006.

52.

Tanaka H, Sakurai Y, Suzuki M, Masunaga S, Mitsumoto T, Fujita K, Kashino G, Kinashi Y, Liu Y, Takada M, et al.: Experimental verification of beam characteristics for cyclotron-based epithermal neutron source (C-BENS). Appl Radiat Isot 2011, 69: 1642-1645. 10.1016/j.apradiso.2011.03.020PubMed

53.

Coderre JA, Turcotte JC, Riley KJ, Binns PJ, Harling OK, Kiger WS: Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation. Technol Cancer Res Treat 2003, 2: 355-375.PubMed

54.

Rogus RD, Harling OK, Yanch JC: Mixed field dosimetry of epithermal neutron beams for boron neutron capture therapy at the MITR-II research reactor. Med Phys 1994, 21: 1611-1625. 10.1118/1.597267PubMed

55.

American Society for Testing and Materials: Standard test method for determining thermal neutron reaction and fluence rates by radioactivation techniques. West Conshohocken, PA; 1997.

56.

Attix FH: Introduction to Radiological Physics and Radiation Dosimetry. Wiley, New York; 1986:475-501.

57.

International Commission on Radiation Units and Measurements: Clinical Neutron Dosimetry, Part 1: Determination of Absorbed Dose in a Patient Treated by External Beams of Fast Neutrons. Bethesda, MD; 1989.

58.

Zamenhof R, Redmond E, Solares G, Katz D, Riley K, Kiger S, Harling O: Monte Carlo-based treatment planning for boron neutron capture therapy using custom designed models automatically generated from CT data. Int J Radiat Oncol Biol Phys 1996, 35: 383-397. 10.1016/0360-3016(96)00084-3PubMed

59.

Palmer MR, Goorley JT, Kiger WS, Busse PM, Riley KJ, Harling OK, Zamenhof RG: Treatment planning and dosimetry for the Harvard-MIT Phase I clinical trial of cranial neutron capture therapy. Int J Radiat Oncol Biol Phys 2002, 53: 1361-1379. 10.1016/S0360-3016(02)02862-6PubMed

60.

Nigg DW: Computational dosimetry and treatment planning considerations for neutron capture therapy. J Neurooncol 2003, 62: 75-86.PubMed

61.

Kiger WS, Lu XQ, Harling OK, Riley KJ, Binns PJ, Kaplan J, Patel H, Zamenhof RG, Shibata Y, Kaplan ID, et al.: Preliminary treatment planning and dosimetry for a clinical trial of neutron capture therapy using a fission converter epithermal neutron beam. Appl Radiat Isot 2004, 61: 1075-1081. 10.1016/j.apradiso.2004.05.008PubMed

62.

Albritton JR: Computational aspects of treatment planning for neutron capture therapy. PhD thesis. Massachusetts Institute of Technology: Nuclear Science and Engineering; 2009.

63.

Riley KJ, Binns PJ, Greenberg DD, Harling OK: A physical dosimetry intercomparison for BNCT. Med Phys 2002, 29: 898-904. 10.1118/1.1473133PubMed

64.

Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T: Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 1998, 39: 325-333.PubMed

65.

Miyashita M, Miyatake S, Imahori Y, Yokoyama K, Kawabata S, Kajimoto Y, Shibata MA, Otsuki Y, Kirihata M, Ono K, Kuroiwa T: Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. J Neurooncol 2008, 89: 239-246. 10.1007/s11060-008-9621-6PubMed

66.

Binns PJ, Riley KJ, Harling OK, Auterinen I, Marek M, Kiger WS: Progress with the NCT international dosimetry exchange. Appl Radiat Isot 2004, 61: 865-868. 10.1016/j.apradiso.2004.05.044PubMed

67.

Binns PJ, Riley KJ, Harling OK, Kiger WS, Munck af Rosenschold PM, Giusti V, Capala J, Skold K, Auterinen I, Seren T: An international dosimetry exchange for boron neutron capture therapy. Part I: Absorbed dose measurements. Med Phys 2005, 32: 3729-3736. 10.1118/1.2132572PubMed

68.

Riley KJ, Binns PJ, Harling OK, Kiger WS, Gonzalez SJ, Casal MR, Longhino J, Larrieu OA, Blaumann HR: Unifying dose specification between clinical BNCT centers in the Americas. Med Phys 2008, 35: 1295-1298. 10.1118/1.2884856PubMed

69.

Riley KJ, Binns PJ, Harling OK, Albritton JR, Kiger WS, Rezaei A, Skold K, Seppälä T, Savolainen S, Auterinen I, et al.: An international dosimetry exchange for BNCT part II: Computational dosimetry normalizations. Med Phys 2008, 35: 5419-5425. 10.1118/1.3005480PubMed

70.

Albritton JR, Kiger WS: Neutron beam source definition techniques for NCT treatment planning. In Proceedings of the 13th International Congress on Neutron Capture Therapy: A New Option Against Cancer. Edited by: Altieri S, Barth RF, Bortolussi S, Roveda L. ENEA, Rome; 2008:571-574.

71.

Albritton JR, Kiger WS: Development of reference problems for neutron capture therapy treatment planning systems. In Advances in Neutron Capture Therapy 2006. Edited by: Nakagawa Y, Kobayashi T, Fukuda H. International Society for Neutron Capture Therapy, Takamatsu, Japan; 2006:496-499.

72.

Locher GL: Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radium Ther 1936, 36: 1-13.

73.

Sweet WH: Practical problems in the past in the use of boron-slow neutron capture therapy in the treatment of glioblastoma multiforme. Proceedings of the First International Symposium on Neutron Capture Therapy 1983, 376-378.

74.

Farr LE, Sweet WH, Robertson JS, Foster CG, Locksley HB, Sutherland DL, Mendelsohn ML, Stickley EE: Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol Radium Ther Nucl Med 1954, 71: 279-293.PubMed

75.

Asbury AK, Ojemann RG, Nielsen SL, Sweet WH: Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol 1972, 31: 278-303. 10.1097/00005072-197204000-00005PubMed

76.

Hatanaka H: Boron neutron capture therapy for brain tumors. In Glioma. Edited by: Karim A, Laws E. Springer-Verlag, Berlin; 1991:233-249.

77.

Nakagawa Y, Hatanaka H: Boron neutron capture therapy. Clinical brain tumor studies. J Neurooncol 1997, 33: 105-115.PubMed

78.

Soloway AH, Hatanaka H, Davis MA: Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J Med Chem 1967, 10: 714-717. 10.1021/jm00316a042PubMed

79.

Chanana AD, Capala J, Chadha M, Coderre JA, Diaz AZ, Elowitz EH, Iwai J, Joel DD, Liu HB, Ma R, et al.: Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery 1999, 44: 1182-1192. discussion 1192–1183PubMed

80.

Diaz AZ: Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol 2003, 62: 101-109.PubMed

81.

Busse PM, Harling OK, Palmer MR, Kiger WS, Kaplan J, Kaplan I, Chuang CF, Goorley JT, Riley KJ, Newton TH, et al.: A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neurooncol 2003, 62: 111-121.PubMed

82.

Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, Liu HB, Wielopolski L, Chanana AD: Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys 1998, 40: 829-834. 10.1016/S0360-3016(97)00891-2PubMed

83.

Wittig A, Hideghety K, Paquis P, Heimans J: Current Clinical Results of the EORTC-Study 11961. In Research and Development in Neutron Capture Therapy. Edited by: Sauerwein W, Moss R, Wittig A. Monduzzi Editore - International Proceedings Division, Bologna; 2002:1117-1122.

84.

Vos MJ, Turowski B, Zanella FE, Paquis P, Siefert A, Hideghety K, Haselsberger K, Grochulla F, Postma TJ, Wittig A, et al.: Radiologic findings in patients treated with boron neutron capture therapy for glioblastoma multiforme within EORTC trial 11961. Int J Radiat Oncol Biol Phys 2005, 61: 392-399. 10.1016/j.ijrobp.2004.06.008PubMed

85.

Wittig A, Sauerwein W, Moss R, Stecher-Rasmussen F, Nivaart V, Grabbe S, Heimans J, Collette L, Loenen A, Buehrmann S, et al.: Early phase II study on BNCT in metastatic malignant melanoma using the boron carrier BPA (EORTC protocol 11011). In Advances in Neutron Capture Therapy 2006. Edited by: Nakagawa Y, Kobayashi T, Fukuda H. International Society for Neutron Capture Therapy, Takamatsu, Japan; 2006:284-287.

86.

Joensuu H, Kankaanranta L, Seppala T, Auterinen I, Kallio M, Kulvik M, Laakso J, Vahatalo J, Kortesniemi M, Kotiluoto P, et al.: Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J Neurooncol 2003, 62: 123-134.PubMed

87.

Kankaanranta L, Koivunoro H, Kortesniemi M, Välimäki P, Seppälä T, Kotiluoto P, Auterinen I, Kouri M, Savolainen S, Joensuu H: BPA-Based BNCT in the treatment of glioblastoma multiforme: A dose escalation study. In 13th International Congress on Neutron Capture Therapy, A New Option Against Cancer; November 2–7; Florence, Italy. Edited by: Zonta A, Altieri S, Roveda L, Barth RF. 2008, 30.

88.

Kankaanranta L, Seppälä T, Koivunoro H, Valimaki P, Beule A, Collan J, Kortesniemi M, Uusi-Simola J, Kotiluoto P, Auterinen I, et al.: L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study. Int J Radiat Oncol Biol Phys 2011, 80: 369-376. 10.1016/j.ijrobp.2010.02.031PubMed

89.

Burian J, Marek M, Rataj J, Flibor S, Rejchrt J, Viererbl L, Sus F: Report on the first patient group of the phase I BNCT trial at the LVR-15 reactor. Int Congress Series 2004, 1259: 27-32.

90.

Capala J, Stenstam BH, Sköld K, Munck af Rosenschold P, Giusti V, Persson C, Brun A, Franzen L, Carlsson J, et al.: Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neurooncol 2003, 62: 135-144.PubMed

91.

Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzen L, Blomquist E, Westlin JE, Bergenheim AT: Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 2008, 88: 183-191. 10.1016/j.radonc.2006.04.015PubMed

92.

Sköld K, Stenstam BH, Diaz AZ, Giusti V, Pellettieri L, Hopewell JW: Boron neutron capture therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. Acta Neurol Scand 2010, 122: 58-62.PubMed

93.

Sköld K, Gorlia T, Pellettieri L, Giusti V, HS B, Hopewell JW: Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br J Radiol 2010, 83: 596-603. 10.1259/bjr/56953620PubMedCentralPubMed

94.

Stenstam BH, Pellettieri L, Sorteberg W, Rezaei A, Skold K: BNCT for recurrent intracranial meningeal tumours - case reports. Acta Neurol Scand 2007, 115: 243-247.PubMed

95.

Pellettieri L, HS B, Rezaei A, Giusti V, Skold K: An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand 2008, 117: 191-197. 10.1111/j.1600-0404.2007.00924.xPubMed

96.

Yamamoto T, Matsumura A, Nakai K, Shibata Y, Endo K, Sakurai F, Kishi T, Kumada H, Yamamoto K, Torii Y: Current clinical results of the Tsukuba BNCT trial. Appl Radiat Isot 2004, 61: 1089-1093. 10.1016/j.apradiso.2004.05.010PubMed

97.

Yamamoto T, Nakai K, Kageji T, Kumada H, Endo K, Matsuda M, Shibata Y, Matsumura A: Boron neutron capture therapy for newly diagnosed glioblastoma. Radiother Oncol 2009, 91: 80-84. 10.1016/j.radonc.2009.02.009PubMed

98.

Kageji T, Nagahiro S, Matsuzaki K, Mizobuchi Y, Toi H, Nakagawa Y, Kumada H: Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma-correlation between radiation dose and radiation injury and clinical outcome. Int J Radiat Oncol Biol Phys 2006, 65: 1446-1455. 10.1016/j.ijrobp.2006.03.016PubMed

99.

Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H: Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. Appl Radiat Isot 2011, 69: 1823-1825. 10.1016/j.apradiso.2011.05.029PubMed

100.

Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada H: Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT). Appl Radiat Isot 2011, 69: 1800-1802. 10.1016/j.apradiso.2011.03.021PubMed

101.

Miyatake S, Kawabata S, Kajimoto Y, Aoki A, Yokoyama K, Yamada M, Kuroiwa T, Tsuji M, Imahori Y, Kirihata M, et al.: Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 2005, 103: 1000-1009. 10.3171/jns.2005.103.6.1000PubMed

102.

Kawabata S, Miyatake S, Kuroiwa T, Yokoyama K, Doi A, Iida K, Miyata S, Nonoguchi N, Michiue H, Takahashi M, et al.: Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res (Tokyo) 2009, 50: 51-60. 10.1269/jrr.08043

103.

Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y, Kumada H, Suzuki M, Maruhashi A, Kirihata M, Ono K: Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol 2009, 91: 199-206. 10.1007/s11060-008-9699-xPubMed

104.

Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K: Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery 2007, 61: 82-90. discussion 90–81 10.1227/01.neu.0000279727.90650.24PubMed

105.

Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A, Kuroiwa T, Asada M, Tanabe H, Ono K: Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg 2006, 105: 898-903.PubMed

106.

Kawabata S, Miyatake S, Hiramatsu R, Hirota Y, Miyata S, Takekita Y, Kuroiwa T, Kirihata M, Sakurai Y, Maruhashi A, Ono K: Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme–study design and current status report. Appl Radiat Isot 2011, 69: 1796-1799. 10.1016/j.apradiso.2011.03.014PubMed

107.

Barth RF, Grecula JC, Yang W, Rotaru JH, Nawrocky M, Gupta N, Albertson BJ, Ferketich AK, Moeschberger ML, Coderre JA, Rofstad EK: Combination of boron neutron capture therapy and external beam radiotherapy for brain tumors. Int J Radiat Oncol Biol Phys 2004, 58: 267-277. 10.1016/S0360-3016(03)01613-4PubMed

108.

Yamamoto T, Nakai K, Nariai T, Kumada H, Okumura T, Mizumoto M, Tsuboi K, Zaboronok A, Ishikawa E, Aiyama H, et al.: The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation. Appl Radiat Isot 2011, 69: 1817-1818. 10.1016/j.apradiso.2011.02.013PubMed

109.

Aiyama H, Nakai K, Yamamoto T, Nariai T, Kumada H, Ishikawa E, Isobe T, Endo K, Takada T, Yoshida F, et al.: A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba. Appl Radiat Isot 2011, 69: 1819-1822. 10.1016/j.apradiso.2011.04.031PubMed

110.

Nakai K, Yamamoto T, Aiyama H, Takada T, Yoshida F, Kageji T, Kumada H, Isobe T, Endo K, Matsuda M, et al.: Boron neutron capture therapy combined with fractionated photon irradiation for glioblastoma: a recursive partitioning analysis of BNCT patients. Appl Radiat Isot 2011, 69: 1790-1792. 10.1016/j.apradiso.2011.03.049PubMed

111.

Smith DR, Chandra S, Barth RF, Yang W, Joel DD, Coderre JA: Quantitative imaging and microlocalizaton of boron-10 in brain tumors and infiltrating tumor cells by SIMS ion microscopy: Relevance to neutron capture therapy. Cancer Res 2001, 61: 8179-8187.PubMed

112.

Hopewell JW, Gorlia T, Pellettieri L, Giusti V, Stenstam BH, Skold K: Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Appl Radiat Isot 2011, 69: 1737-1740. 10.1016/j.apradiso.2011.03.022PubMed

113.

Ariyoshi Y, Miyatake S, Kimura Y, Shimahara T, Kawabata S, Nagata K, Suzuki M, Maruhashi A, Ono K, Shimahara M: Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep 2007, 18: 861-866.PubMed

114.

Kimura Y, Ariyoshi Y, Miyatake S, Shimahara M, Kawabata S, Ono K: Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: a case report. Int J Oral Maxillofac Surg 2009, 38: 293-295. 10.1016/j.ijom.2008.12.010PubMed

115.

Kimura Y, Ariyoshi Y, Shimahara M, Miyatake S, Kawabata S, Ono K, Suzuki M, Maruhashi A: Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node. Appl Radiat Isot 2009, 67: S47-S49. 10.1016/j.apradiso.2009.03.019PubMed

116.

Suzuki M, Sakurai Y, Nagata K, Kinashi Y, Masunaga S, Ono K, Maruhashi A, Kato I, Fuwa N, Hiratsuka J, Imahori Y: Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 2006, 66: 1523-1527. 10.1016/j.ijrobp.2006.07.1373PubMed

117.

Fuwa N, Suzuki M, Sakurai Y, Nagata K, Kinashi Y, Masunaga S, Maruhashi A, Imahori Y, Kodaira T, Tachibana H, et al.: Treatment results of boron neutron capture therapy using intra-arterial administration of boron compounds for recurrent head and neck cancer. Br J Radiol 2008, 81: 749-752. 10.1259/bjr/65306248PubMed

118.

Aihara T, Hiratsuka J, Nishhiike S, Morita N, Uno M, Maruhashi A, Kumada H, Ono K, Harada T: Boron neutron capture therapy for head and neck epithelial carcinomas other than SCC. In 13th International Congress on Neutron Capture Therapy, A New Option Against Cancer; November 2–7; Florence, Italy. Edited by: Zonta A, Altieri S, Roveda L, Barth RF. 2008, 31-33.

119.

Aihara T, Morita N, Hiratsuka J, Ono K, Harada T, et al.: BNCT for advanced or recurrent head and neck cancer. In Special Issue: 14th International Congress on Neutron Capture Therapy. Edited by: Kreiner AJ, Appl Radiat I. 2011, 25-28.

120.

Fukutsuji K, Aihara T, Hiratsuka J, Kumada H, Ono K, Sakurai Y, Fukuda H, Morita N, Imajo Y: Boron neutron capture therapy for patients with melanomas of head-and-neck. In 13th International Congress on Neutron Capture Therapy, A New Option Against Cancer; November 2–7; Florence, Italy. Edited by: Zonta A, Altieri S, Roveda L, Barth RF. 2008, 83-85.

121.

Kankaanranta L, Saarilahti K, Makitie A, Valimaki P, Tenhunen M, Joensuu H: Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement. Radiother Oncol 2011, 99: 98-99. 10.1016/j.radonc.2011.02.008PubMed

122.

Wang LW, Wang SJ, Chu PY, Ho CY, Jiang SH, Liu YW, Liu YH, Liu HM, Peir JJ, Chou FI, et al.: BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor. Appl Radiat Isot 2011, 69: 1803-1806. 10.1016/j.apradiso.2011.03.008PubMed

123.

Wang LW, Wang SJ, Chu PY, Ho CY, Jiang SH, Chou FI, Liu YWH, Liu YH, Liu HM, Peir JJ, et al.: Preliminary clinical experience of boron neutron capture therapy for locally recurrent head and neck cancer at Tsing Hua Open Pool Reactor. In The Front Edge of BNCT Development: Proceedings of the 6th Young Researchers Boron Neutron Capture Therapy Meeting; Dec. 4–8, 2011; Hsinchu, Taiwan. Edited by: Jiang SH, Liu Y-H. 2011, 257.

124.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352: 987-996. 10.1056/NEJMoa043330PubMed

125.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10: 459-466. 10.1016/S1470-2045(09)70025-7PubMed

Title: Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer
Authors: Rolf F Barth
MGraca H Vicente
Otto K Harling
WS Kiger III
Kent J Riley
Peter J Binns
Franz M Wagner
Minoru Suzuki
Teruhito Aihara
Itsuro Kato
Shinji Kawabata
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2012
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-7-146

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells

Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: A pilot study

The effects of high dose and highly fractionated radiation on distraction osteogenesis in the murine mandible

Autophagy inhibition plays the synergetic killing roles with radiation in the multi-drug resistant SKVCR ovarian cancer cells

Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor®)

Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies